Xeris Biopharma Holdings (XERS) Cash from Operations Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 4,440.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,440.11% |
| Mar 31, 2026 | 198.39% |
| Dec 31, 2025 | 914.84% |
| Sep 30, 2025 | 321.94% |
| Jun 30, 2025 | 101.76% |
| Mar 31, 2025 | 50.59% |
| Dec 31, 2024 | -73.56% |
| Sep 30, 2024 | 43.16% |
| Jun 30, 2024 | 24.71% |
| Mar 31, 2024 | 22.33% |
| Dec 31, 2023 | 146.35% |
| Sep 30, 2023 | 17.71% |
| Jun 30, 2023 | 33.31% |
| Mar 31, 2023 | 46.00% |
| Dec 31, 2022 | 44.31% |
| Sep 30, 2022 | 21.48% |
| Jun 30, 2022 | -2.93% |
| Mar 31, 2022 | -102.07% |
| Dec 31, 2021 | -166.32% |